In vivo modelling of cutaneous T-cell lymphoma: The role of SOCS1

被引:3
|
作者
Luo, Yixin [1 ]
Vermeer, Maarten H. [1 ]
de Gruijl, Frank R. [1 ]
Zoutman, Willem H. [1 ]
Sluijter, Marjolein [2 ]
van Hall, Thorbald [2 ]
Tensen, Cornelis P. [1 ]
机构
[1] Leiden Univ Med Ctr, Dept Dermatol, Leiden, Netherlands
[2] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Leiden, Netherlands
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
cutaneous T cell lymphoma; mycosis fungoides; transgenic mouse; in vivo modeling; inflammation; CHRONIC SKIN INFLAMMATION; MOUSE EPIDERMIS REVEAL; CYTOKINE SIGNALING-1; IFN-GAMMA; STAT3; EXPRESSION; CANCER; ACTIVATION; SUPPRESSOR; SUPPRESSOR-OF-CYTOKINE-SIGNALING-1;
D O I
10.3389/fonc.2022.1031052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionMycosis fungoides (MF), the most common type of Cutaneous T cell Lymphoma (CTCL), is characterized by an inflamed skin intermixed with proliferating malignant mature skin-homing CD4+ T cells. Detailed genomic analyses of MF skin biopsies revealed several candidate genes possibly involved in genesis of these tumors and/or potential targets for therapy. These studies showed, in addition to common loss of cell cycle regulator CDKN2A, activation of several oncogenic pathways, most prominently and consistently involving JAK/STAT signaling. SOCS1, an endogenous inhibitor of the JAK/STAT signaling pathway, was identified as a recurrently deleted gene in MF, already occurring in the earliest stages of the disease. MethodsTo explore the mechanisms of MF, we create in vivo mouse models of autochthonous CTCLs and these genetically engineered mouse models (GEMMS) can also serve as valid experimental models for targeted therapy. We describe the impact of allelic deletion of Socs1 in CD4 T cells of the skin. To achieve this, we crossed inducible Cre-transgenic mice in the CD4 lineage with transgenic mice carrying floxed genes of Socs1. We first determined optimal conditions for Socs1 ablation with limited effects on circulating CD4 T-cells in blood. Next, we started time-course experiments mimicking sustained inflammation, typical in CTCL. FACS analysis of the blood was done every week. Skin biopsies were analyzed by immunocytochemical staining at the end of the experiment. ResultsWe found that the Socs1 knockout transgenic group had thicker epidermis of treated skin compared with the control group and had more CD3 and CD4 in the skin of the transgenic group compared to the control group. We also noted more activation of Stat3 by staining for P-Stat3 in Socs1 knockout compared to wt CD4+T cells in the skin. The results also indicated that single copy loss of Socs1 in combination with sustained inflammation is insufficient to start a phenotype resembling early stage mycosis fungoides within eight weeks in these mice. ConclusionIn sum, we developed and optimized an autochthonous murine model permitting selective knockout of Socs1 in skin infiltrating CD4 T-cells. This paves the way for more elaborate experiments to gain insight in the oncogenesis of CTCL.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma
    Duvic, Madeleine
    DERMATOLOGIC CLINICS, 2015, 33 (04) : 757 - +
  • [22] Emerging drugs for the treatment of cutaneous T-cell lymphoma
    Cheng, Melissa
    Zain, Jasmine
    Rosen, Steven T.
    Querfeld, Christiane
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 45 - 54
  • [23] Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma
    Van-de-Velde, Vanessa
    Zhou, Youwen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2019, 23 (03) : 319 - 327
  • [24] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Prince, H. Miles
    Newland, Kate M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 625 - 634
  • [25] New and emerging therapies in cutaneous T-cell lymphoma
    Roccuzzo, Gabriele
    Macagno, Nicole
    Giordano, Silvia
    Fava, Paolo
    Quaglino, Pietro
    DERMATOLOGY REPORTS, 2025, 17 (01)
  • [26] Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma
    Fanok, Melania H.
    Sun, Amy
    Fogli, Laura K.
    Narendran, Vijay
    Eckstein, Miriam
    Kannan, Kasthuri
    Dolgalev, Igor
    Lazaris, Charalampos
    Heguy, Adriana
    Laird, Mary E.
    Sundrud, Mark S.
    Liu, Cynthia
    Kutok, Jeff
    Lacruz, Rodrigo S.
    Latkowski, Jo-Ann
    Aifantis, Iannis
    Odum, Niels
    Hymes, Kenneth B.
    Goel, Swati
    Koralov, Sergei B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : 1116 - 1125
  • [27] SOCS1 downregulation in dendritic cells promotes memory T-cell responses
    Aldrich, Melissa
    Sanders, Denise
    Lapteva, Natasha
    Huang, Xue F.
    Chen, Si-Yi
    VACCINE, 2008, 26 (08) : 1128 - 1135
  • [28] Cytomegalovirus: its potential role in the development of cutaneous T-cell lymphoma
    Ballanger, F.
    Bressollette, C.
    Volteau, C.
    Planche, L.
    Dreno, B.
    EXPERIMENTAL DERMATOLOGY, 2009, 18 (06) : 574 - 576
  • [29] Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma
    Nakai, Shuichi
    Kiyohara, Eiji
    Watanabe, Rei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [30] Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma
    Suga, Hiraku
    Sugaya, Makoto
    Miyagaki, Tomomitsu
    Kawaguchi, Makiko
    Morimura, Sohshi
    Kai, Hiromichi
    Kagami, Shinji
    Ohmatsu, Hanako
    Fujita, Hideki
    Asano, Yoshihide
    Tada, Yayoi
    Kadono, Takafumi
    Sato, Shinichi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2013, 23 (05) : 629 - 635